The peptide protocol that honestly failed
An athlete ran a 10-week BPC-157 trial against a clean baseline — and let the data say it didn't move.
Context
Recurring tendinopathy, three previous self-experiments with peptides judged as "felt better," no baseline, no stopping rule, no honest read.
The shift
Before the next protocol they spent four weeks recording soreness, training load, sleep, and a single pain score, then ran a 10-week single-variable trial with AI holding the structure and weekly check-ins.
Approach (in shape, not in recipe)
A defensible personal n=1 with a pre-registered outcome, a clean baseline, and a stopping rule — graded against the user's own normal week-to-week variability rather than an influencer's before/after photo.
What an honest observer would notice
The post-protocol pain trend sat inside baseline noise. The user concluded honestly that this peptide, for this issue, in this body, did not produce a signal worth the cost or the off-label exposure.
Recommended next